Evaluating Trump's Executive Orders on Drug Pricing

During his second term, President Donald Trump issued a significant number of executive orders, including one aimed at drug pricing titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” This order directed various government agencies to align American drug prices with those paid by developed nations. On July 31, 2021, Trump sent letters to 17 pharmaceutical manufacturers outlining steps to reduce prescription drug prices based on international benchmarks. However, the executive orders primarily benefit uninsured individuals, leading to concerns about the overall effectiveness and potential savings.

The Hill

Historically, legislation has proven to be the most effective means of addressing drug pricing issues. The Hatch-Waxman Act of 1984 established a framework for generic drug competition, while the Inflation Reduction Act of 2021 allowed Medicare to negotiate drug prices, resulting in estimated savings of $19 billion. This act also introduced a cap on out-of-pocket costs for seniors, limiting their expenses to $2,100 for Medicare Part D-covered drugs by 2026. Critics argue that executive actions, including Trump's, have not yielded significant results compared to legislative measures.

The HillBloomberg Government

The Centers for Medicare and Medicaid Innovation proposed two demonstration models to leverage the Medicare Inflation Rebate Program, which would utilize international pricing to secure additional rebates for Medicare. However, these models are complex and face potential legal challenges. Critics, including Wendell Primus, a visiting fellow at the Brookings Institution, emphasize that relying on executive orders and complicated demonstrations is insufficient. They advocate for legislative action to ensure substantial savings in drug costs.

The Hill

Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services, indicated that any legislation to codify Trump's most-favored-nation proposal must consider the pharmaceutical industry's needs. He expressed concerns that poorly structured legislation could lead to more drastic measures by future administrations, potentially harming the industry and stifling innovation.

Bloomberg Government

While Trump's executive orders have drawn attention to the issue of high drug prices, the consensus among experts is that legislative action is necessary for meaningful change. The Inflation Reduction Act has already demonstrated effectiveness in reducing costs, and further legislative expansions could enhance savings for taxpayers and patients. The ongoing debate highlights the complexity of drug pricing reform and the need for a balanced approach that addresses both consumer needs and industry sustainability.

The Hill

• “If it’s not done right, a future administration will take more drastic, draconian steps in ways that would hurt this industry.” — Mehmet Oz, Administrator, Centers for Medicare & Medicaid Services

Bloomberg Government

• “The policy track record to date is clear that the only significant progress this century in advancing the goal of lowering drug prices has been through legislation in the form of the Inflation Reduction Act.” — Wendell Primus, Visiting Fellow, Brookings Institution

The Hill

There are discrepancies regarding the effectiveness of Trump's executive orders compared to legislative measures. While some sources argue that executive actions have minimal impact, others highlight the need for legislative frameworks to achieve substantial savings. Additionally, the operational complexities of proposed demonstration models may hinder their implementation and effectiveness.

The Hill